DOCSLIB.ORG

1. Guidelines for the Management of Agitation in Advanced Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
1. Guidelines for the Management of Agitation in Advanced Cancer 1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER 1.1 GENERAL PRINCIPLES There are many causes of agitation in palliative care patients, which makes 1 recommendations for treatment difficult. Agitation in the dying phase is well recognised but poorly defined and management can be very difficult. Reversible causes should be corrected where possible. The aim of treatment 2, 3, 4, 5 should always be to control the agitation or restlessness. Management of a patient who is agitated may include non-pharmacological and 1 pharmacological measures. Medication used should be titrated to control the agitation and not with the intention of sedation. Medication can be administered intermittently or via a continuous infusion. The 6, 7 effect of sedating medication on the conscious level will vary between individual patients. Sedation can be defined as: “A medical procedure used to palliate symptoms refractory to 8 standard treatment by intentionally diminishing the conscious level.” 1.2 GUIDELINES It may be difficult to differentiate between delirium and agitation. Delirium should be excluded by using the DSM IV criteria for the diagnosis of delirium (see Guidelines for the Management of Delirium in Advanced Cancer). 9 [Level 4] Common causes of agitation in palliative care patients are listed in Table 1.1 Table 1.1 Causes of agitation 1, 10 [Level 4] Anxiety Dyspnoea Biochemical abnormalities Pain Cerebral tumour Psychiatric illness Constipation Terminal agitation Depression Urinary retention Drugs Withdrawal of alcohol / nicotine /sedative drugs Drugs are a common cause of agitation and include: corticosteroids; benzodiazepines (paradoxical agitation) and opioids. Dopamine antagonists such as haloperidol, levomepromazine and olanzapine (akathisia) may also cause cognitive decline and dementia due to the acetylcholine effects. 1 [Level 4] If a patient is agitated it is important to exclude reversible causes and treat where appropriate.4, 5 [Level 4] Non-pharmacological measures are important in the management of an agitated patient. These may include reassurance, presence of familiar faces and use of a well-lit and quiet room. Psychological and spiritual support should be offered where appropriate. 10 [Level 4] Nicotine replacement therapy may be used where agitation is secondary to nicotine withdrawal. 4, 5 [Level 4] Midazolam is the drug of choice for the management of agitation or restlessness at the end of life. 11 [Level 3] The intention of treatment should be to control the symptom of agitation or restlessness. However, at times this may result in a decreased level of consciousness. The drug doses should be titrated to achieve symptom control of the agitation. 6 [Level 4] The aim of treatment, and any expected change in level of consciousness, should be discussed with the patient, relatives and multi-disciplinary team where possible.7 [Level 4] The aim of treatment, and any expected change in the level of consciousness, should be documented in the case notes.7 [Level 4] Where treatment of agitation results in continuous sedation, the underlying disease process should be advanced and irreversible, and death expected in hours to days. 6 [Level 2++] Table 1.2 lists the pharmacological options for the symptomatic management of agitation. 4, 5, 12,13 [Level 4] Figure 1.1 illustrates a suggested approach to the pharmacological management of terminal agitation. 4, 5 [Level 4] Where the patient is shown to lack the capacity to consent to treatment, the Mental Capacity Act 2005 must be followed. The Lasting Power of Attorney, Advance Decisions and Independent Mental Capacity Advocates should be utilised where appropriate. 12 [Level 4] Figure 1.1 Pharmacological management of terminal agitation in advanced cancer 4 [Level 4] Agitated patient in the terminal phase. Review the medication and check for reversible causes. Is the patient able to swallow? YES NO Prescribe diazepam 2mg-15mg Prescribe midazolam 2.5mg-5mg orally daily in divided doses or subcutaneously prn as bolus injection. lorazepam 500microgram-1mg Consider starting subcutaneous bd and/or prn sublingually. infusion of midazolam via a syringe Review patient on a four hourly driver over 24 hours. basis. If patient remains agitated, Starting dose: 10mg (see Table 1.2) may need to convert to parenteral Seek specialist advice if dose > 30mg medication. is considered Assess response 4 hourly. Clinical condition will determine if drugs need reducing and / or stopping. COMPLETE PARTIAL NO RESPONSE RESPONSE RESPONSE Continue Add second line agent. Use Switch to regimen. Levomepromazine. Levomepromazine. Dose range: 25mg-200mg Dose range: 25mg-200mg subcutaneously via syringe subcutaneously via driver over 24 hours. syringe driver over 24 hours. Prescribe subcutaneous stats of 12.5mg-25mg as Prescribe subcutaneous breakthrough medication. stats of 12.5mg-25mg as breakthrough medication. NB In patients with cerebral tumours/history of seizures, midazolam should be continued (see Table 1.2). PARTIAL / NO RESPONSE NO RESPONSE ALL DRUGS SHOULD BE Change to Phenobarbital. TITRATED Give 100mg-200mg bolus intramuscular injections. Start ACCORDING TO continuous infusion: 600mg-1200mg subcutaneously via a CLINICAL NEED syringe driver over 24 hours. AND RESPONSE. Table 1.2 Pharmacological options for the symptomatic management of agitation in advanced cancer 4, 5, 12, 13, 14 [Level 4] Name of drug / Dose and route of Side effects Comments Class of drug administration Lorazepam 500 microgram-1mg bd Possible risk of Not for use in syringe driver. and prn sublingually. paradoxical Short acting Can develop tolerance. Maximum dose is 4mg per agitation. benzodiazepine 24 hours. Diazepam 2mg-5mg tds and prn Possible risk of Not for use in syringe driver. orally. paradoxical Long acting Can develop tolerance. agitation. benzodiazepine 10mg via rectal route prn. 2mg-10mg via intravenous route prn. Midazolam 2.5mg-10mg prn via Possible risk of Will not improve cognition in subcutaneous route. paradoxical delirium. Can develop tolerance. Short acting agitation. Flumazenil is the reversing benzodiazepine 10mg-30mg ** 14 agent. subcutaneously via syringe driver over 24 hours. **If a dose > 30mg / 24 hours is being considered, seek specialist palliative care advice. Doses of up to 100mg / 24 hours have been used but only when the addition of an antipsychotic such as levomepromazine is inappropriate. If patient has received an enzyme inducer such as carbamazepine or phenytoin the dose may need reducing after 3- 5 days as the enzyme induction wears off. Levomepromazine 12.5mg-200mg High doses may May lower the threshold for subcutaneously over 24 precipitate seizures. Therefore in patients Long acting hours for management of seizures. with a history of seizure / phenothiazine agitation. cerebral tumours consider the addition of midazolam in a Stat doses can vary CSCI. between 12.5mg-50mg subcutaneously. Can also use orally for the control of agitation. Phenobarbital Usually given via Use intramuscular injections for parenteral route in this breakthrough medication. Long acting barbiturate situation. Use 100mg- Do not mix with other drugs in a 200mg intramuscular stat syringe driver. injections. Can use 600mg- 2400mg subcutaneously There is anecdotal evidence that via syringe driver over 24 get fewer site reactions if use hours. sodium chloride 0.9% as diluent, although water can be used. Can be given intravenously. 1.3 STANDARDS 1. Reversible causes of agitation should be treated where appropriate. 4, 5 [Grade D] 2. All patients should have a clinical examination at the initial assessment of agitation.4, 5 [Grade D] 4, 5 3. All patients should have a review of medication at the initial assessment of agitation. [Grade D] 7 4. The reason for the use of psychotropic medication should be documented in the case notes. [Grade D] 5. Patients should be reviewed every four hours to ensure adequate symptom control.7 [Grade D] 6. If a health care professional feels they may be shortening life by the use of sedation they should contact senior / specialist help for advice. 7, 13 [Grade D] 1.4 REFERENCES 1. Centeno C, Sanz A, Bruera E. Delirium in advanced cancer patients. Palliat Med 2004; 18: 184-194. 2. Cherny NI, Portenoy RK. Sedation in the management of refractory symptoms: guidelines for evaluation and treatment. J Palliat Care 1994; 10(2): 31-38. 3. Chater S, Viola R, Paterson J, Jarvis V. Sedation for intractable distress in the dying - a survey of experts. Palliat Med 1998; 12(4): 255-269. 4. Twycross R. Psychological symptoms. In: Twycross R, (editor). Symptom Control in Advanced Cancer. 2nd edition. Oxford: Radcliffe Medical Press; 1997. p. 92-115. 5. Twycross R, Wilcock A. (editors). Palliative Care Formulary. 3rd edition. Nottingham: Palliativedrugs.com Ltd; 2007. p. 115-141 6. De Graeff A, Dean M. Palliative sedation therapy in the last weeks of life: a literature review and recommendations for standards. J Palliat Med 2007; 10: 67-85. 7. Merseyside and Cheshire Palliative Care Network Audit Group. Management of Agitation in Advanced Cancer. Expert Consensus. July 2008. 8. Morita T, Tsunoda J, Inoue S, Chihara S. Do hospice clinicians sedate patients intending to hasten death? J Palliat Care 1999; 15(3): 20-23. 9. American Psychiatric Association. Practice guidelines for the treatment of patients with delirium. Am J Psych 1999; 156 (5 supp): 1-2. 10. Furst CJ, Doyle D. The Terminal Phase. In: Doyle D, Hanks G, Cherny N, Calman K (eds). Oxford Textbook of Palliative Medicine. 3rd edition. Oxford: Oxford University Press; 2005. p.1117-1133. 11. Bottomley DM, Hanks G. Subcutaneous midazolam infusion in palliative care. J Pain Symptom Manage 1990; 5: 259-261. 12. Department for Constitutional Affairs. Mental Capacity Act 2005 Code of Practice. London 2007. Available from: http://www.publicguardian.gov.uk/mca/code-of-practice.htm. [Last accessed 23 May 2009]. 13. Sykes NP, Thorns A. The use of opioids and sedatives at the end of life. Lancet Oncol 2003; 4: 312-318. 14. National Patient Safety Agency. Rapid Response Report NPSA / 2008 / RRR011. Reducing risk of overdose with midazolam injections in adults.
Load more

Recommended publications
  • Sedation for Palliative Purposes Guideline
    1 Sedation for Palliative Purposes Guideline July 18, 2017 July 18, 2017 2 WRHA Regional Committee Members Co-Chairs Dr. Mike Harlos, Medical Director, WRHA Adult and Pediatric Palliative Care Program Lori Embleton, Program Director, WRHA Palliative Care Program Committee Members Jawad Barlas, Pharmacy, Riverview Health Centre Joanne Browning RN, Critical Care, Health Sciences Centre Dr. Garnet Crawford, WRHA Palliative Care Physician Consultant Jennifer Dunsford RN, WRHA Regional Ethics Dr. Aviva Goldberg, Pediatric Nephrology and Ethics Dr. Duane Hartley, Family Medicine and Palliative Care Dr. Tim Hiebert, Internal Medicine Dr. Chris Hohl, Pediatrics Pat Murphy, Clinical Ethicist, St. Boniface Hospital Janice Nesbitt RN, Clinical Nurse Specialist, WRHA Palliative Care Program Dr. Shaundra Popowich, Womens’ Health Tracy Thiele RN, WRHA Projects Manager and Liaison George Webster, Clinical Ethicist, St. Boniface Hospital Luana Whitbread RN, Clinical Nurse Specialist, WRHA Long Term Care Dr. Kim Wiebe, Critical Care Dr. Cornie Woelk, Prairie Mountain Health Physician July 18, 2017 3 WRHA Clinical Practice Guideline: Sedation for Palliative Purposes (SPP) WRHA Regional Committee Members ……………………………………………………………………………………… 2 Purpose and Scope of guideline ……………………………………………………………………………………………….. 4 Levels of Evidence ……………………………………………………………………………………………………………………. 5 Definition …………………………………………………………………………………………………………………………………. 5 Sedation for Palliative Purposes vs. Medical Assist in Dying ……………………………………………………… 6 Indications …………………………………………………………………………………………………………………………………
    [Show full text]
  • Euthanasia, Assisted-Suicide, and Palliative Sedation: a Brief Clarification and Reinforcement of the Moral Logic Peter A
    Online Journal of Health Ethics Volume 14 | Issue 2 Article 4 Euthanasia, Assisted-Suicide, and Palliative Sedation: A Brief Clarification and Reinforcement of the Moral Logic Peter A. DePergola II University of Massachusetts eM dical School - Baystate; College of Our Lady of the Elms, [email protected] Follow this and additional works at: https://aquila.usm.edu/ojhe Part of the Applied Ethics Commons, Bioethics and Medical Ethics Commons, Medical Humanities Commons, and the Palliative Care Commons Recommended Citation DePergola, P. A. (2018). Euthanasia, Assisted-Suicide, and Palliative Sedation: A Brief Clarification and Reinforcement of the Moral Logic. Online Journal of Health Ethics, 14(2). http://dx.doi.org/ 10.18785/ojhe.1402.04 This Article is brought to you for free and open access by The Aquila Digital Community. It has been accepted for inclusion in Online Journal of Health Ethics by an authorized editor of The Aquila Digital Community. For more information, please contact [email protected]. Euthanasia, Assisted Suicide, and Palliative Sedation: A Brief Clarification and Reinforcement of the Moral Logic Peter A. DePergola II University of Massachusetts Medical School College of Our Lady of the Elms ABSTRACT A persistent misunderstanding of the moral distinctions between the practices of euthanasia, assisted suicide, and palliative sedation suggests a critical need to revisit the relationship each shares with licit medical practice in the context of palliative care. To that end, this essay grounds its arguments in two, straightforward premises: (i) the licitness of medical practice is largely determined by the balance between (a) good ends, (b) proportionate means, (c) appropriate circumstances, and (d) benevolent intentions; and (ii) whereas palliative sedation employs criteria A-D (above), both euthanasia and assisted suicide fail to secure criteria A-C.
    [Show full text]
  • Continuous Deep Palliative Sedation: an Ethical Analysis
    Continuous Deep Palliative Sedation: An Ethical Analysis Dr Lalit Kumar Radha Krishna Senior Consultant in Palliative Medicine MBChB Liverpool, MRCP (London), MA in Ethics in Cancer and Palliative Care (Keele) A thesis submitted For the degree of Doctor of Philosophy Centre for Biomedical Ethics National University of Singapore 2013 i ii Acknowledgements For those who have inspired me, guided me, stood with me and supported me For my parents who made me the man I am & For my wife and son who inspire me to be more ~ words fail iii iv Table of Contents Declaration ................................................................................................................... i Acknowledgement ....................................................................................................... iii Summary ................................................................................................................... xiii List of Tables.............................................................................................................xvii List of Figures............................................................................................................xix Acronyms....................................................................................................................xxi INTRODUCTION ......................................................................................................1 Controversies surrounding the application of palliative sedation and terminal sedation ...............................................................................................2
    [Show full text]
  • Palliative Sedation in Patients with Cancer Marco Maltoni, MD, and Elisabetta Setola, MD
    Communication between patients, their relatives, and health care staff is very important when administered palliative sedation. Photo courtesy of Lisa Scholder. Organic Walk, 16" × 24". Palliative Sedation in Patients With Cancer Marco Maltoni, MD, and Elisabetta Setola, MD Background: Palliative sedation involves the use of sedative medication to relieve refractory symptoms in patients by reducing their level of consciousness. Although it is considered an acceptable clinical practice from most ethical points of view, palliative sedation is still a widely debated procedure and merits better un- derstanding. Methods: The relevant medical literature pertaining to palliative sedation was analyzed and reviewed from various technical, relational, and bioethical perspectives. Results: Proportionate palliative sedation is considered to be the most clinically appropriate modality for performing palliative sedation. However, guidelines must be followed to ensure that it is performed correctly. Benzodiazepines represent the first therapeutic option and careful monitoring of dosages is essential to avoid oversedation or undersedation. Conclusions: Proportionate palliative sedation is used to manage and relieve refractory symptoms in patients with cancer during their last days or hours of life. Evidence suggests that its use has no detrimental effect on survival. A different decision-making process is used to manage the withdrawal of hydration than the process used to determine whether proportionate palliative sedation is appropriate. Communication
    [Show full text]
  • The Waterloo Wellington Palliative Sedation Protocol
    The Waterloo Wellington Palliative Sedation Protocol Waterloo Wellington Interdisciplinary HPC Education Committee; PST Task Force Chair: Dr. Deborah Robinson MD CCFP(F), Focused practice in Oncology and Palliative Care Co-chairs: Cathy Joy, Palliative Care Consultant, Waterloo Region Chris Bigelow, Palliative Care Consultant, Wellington County Revision due: November 2016 Last revised and activated: November 13, 2013 Committee responsible for revisions: WW Interdisciplinary HPC Education Committee Table of Contents Purpose and Definitions .................................................................................................................... 2 Indications for the use of PST .............................................................................................................. 3 Criteria for Initiation of PST ............................................................................................................... 4 Process ............................................................................................................................................. 4 Documentation for Initiation of PST .................................................................................................. 5 Medications ......................................................................................................................................... 6 1st Line (Initiating PST) ...................................................................................................................... 6 2nd Line (When 1st
    [Show full text]
  • Dyspnea: the Top Things You Need to You Know!
    Dyspnea: The top things you need to you know! Dr. Megan Sellick & Dr. Lawrence Lee Edmonton Zone Palliative Care Program Faculty / Presenter Disclosure • Faculty: Dr. Lawrence Lee • Relationships with commercial interests: • Grants/Research Support: none • Speakers Bureau/Honoraria: none • Consulting Fees: none • Other: none Faculty / Presenter Disclosure • Faculty: Dr. Megan Sellick • Relationships with commercial interests: • Grants/Research Support: none • Speakers Bureau/Honoraria: none • Consulting Fees: none • Other: none Disclosure of Commercial Support • This program has received financial support from: none • This program has received in-kind support from: none Objectives By the end of our time together, you will be able to : • Recognize the subjective nature of dyspnea • Provide an initial management plan for dyspnea (non-pharmacological and pharmacological) • Briefly describe “palliative sedation” and describe the medication used Dyspnea This man has metastatic lung cancer. Which of the following is the best measure of his dyspnea? A- respiratory rate B- use of accessory breathing muscles C- oxygen requirements D- oxygen saturations E- all of the above F- none of the above (patient’s report is best) Dyspnea Definition: “feeling like one cannot breathe well enough” American Thoracic Society: “a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity.” Dyspnea Overall Management Approach: Screen+Assess Identify Cause(s) Management Underlying Cause Symptoms Dyspnea
    [Show full text]
  • Edmonton Zone Palliative Care Program
    Palliative Sedation Guideline Edmonton Zone Palliative Care Program Title: Palliative Sedation GUIDELINE Date Approved: Original version in September 2006 and revised in October 2015 Approved By: Edmonton Zone Palliative Care Program, Practice Development and Quality Committee Date of Next Review: October 2018 A. PURPOSE: To provide guidance when considering Palliative Sedation as a form of palliation for intractable symptoms in an appropriate setting and time frame. B. STAKEHOLDER INVOLVEMENT: • This guideline was developed by health care professionals with expertise in palliative care. The disciplines of nursing, pharmacy and medicine were represented with additional consultation with ethics and spiritual care • Patients’ views and preferences were not specifically sought in developing the guideline, given the medically frail nature of this population. However, the guidelines reflect the developers’ observations of patients’ experiences • The guideline is intended for use by palliative care consultants, as well as other physicians and nurses involved in the care of palliative care patients • Although the guideline has not been piloted among target users, it reflects current practice in the Edmonton Zone Palliative Care Program C. DEVELOPMENT: • The articles were identified through a search of MEDLINE from 1985 to 2005, using the search term “sedation”; subject heading “palliative care”, “terminal care”, “delirium”, “neoplasm”, “hypnosis”, and “sedative”; combined with “refractory symptom”, subject heading “palliative care”, “pain”,
    [Show full text]
  • Be a Hero to a Dying Patient: Symptom Management At
    BEAHERO TO A DYING PATIENT: SYMPTOM MANAGEMENT AT END- OF LIFE. Robert G. Wahler, Jr., Pharm.D., BCGP, FASCP, CPE Clinical Assistant Professor, UB SPPS Director, Clinical Pharmacy Services, Niagara Hospice 1 2019 Wahler RG LEARNING OBJECTIVES 1. Identify common symptoms experienced by patients with advanced illness. 2. Select or recommend medication options for specific palliative symptoms. 3. Discuss various pharmacologic interventions for common symptoms. 4. Define treatment measures in the last hours of life. 2 INTRODUCTION 2.8 million death/year in US, 1.4 million in hospice. It is important to address and manage each end-of-life symptom to improve the quality of life for the patient. An interdisciplinary team approach is beneficial throughout the care of the patient. This is evident when addressing more psychologically based symptoms, such as delirium. 3 INTRODUCTION The ASHP Guidelines on the Pharmacist's Role in Palliative and Hospice Care - Essential Clinical and Administrative Roles Direct patient care Optimize the outcomes of symptom management and palliative care patients through the expert provision of evidence-based, patient-centered medication therapy as an integral part of an interdisciplinary team Serve as an authoritative resource on the optimal use of medications in symptom management and palliative care Anticipate transitions of care when recommending, initiating, modifying, or discontinuing pharmacotherapy for pain and symptoms Medication order review and reconciliation Manage and improve the medication-use process in patient care settings Education and medication counseling Demonstrate excellence in the provision of medication counseling to patients, caregivers, and families Administrative roles 4 Ensure safe use of medications in the treatment of pain and symptoms Medication supply chain management Herndon CM, Nee D, Atayee RS, Craig DS, Lehn J, Moore PS, Nesbit SA, Ray JB, Scullion BF, Wahler RG, Waldfogel J.
    [Show full text]
  • Palliative Sedation Therapy (PST) Protocol Is an Interprofessional Peer- Reviewed, Evidence-Informed Clinical Resource
    The Waterloo Wellington Palliative Sedation Therapy Protocol Waterloo Wellington Interdisciplinary HPC Education Committee: PST Task Force Last Revised: December 2019 Next Review Date: December 2022 Table of Contents Purpose ______________________________________________________________________________ 1 Introduction __________________________________________________________________________ 3 Defining Palliative Sedation Therapy _____________________________________________________________ 3 When to Consider Palliative Sedation Therapy _______________________________________________ 5 Criteria for Initiating Palliative Sedation Therapy ____________________________________________ 7 Criteria _____________________________________________________________________________________ 7 Palliative Sedation Therapy Process ______________________________________________________________ 7 Patient Assessment ___________________________________________________________________________________ 7 Consent Process ______________________________________________________________________________________ 8 Care Planning ________________________________________________________________________________________ 8 Palliative Sedation Therapy Medications __________________________________________________ 11 Monitoring _________________________________________________________________________________ 12 Table 1. Common PST Medications ______________________________________________________________________ 15 Family and Team Support ______________________________________________________________
    [Show full text]
  • Position Statement on Euthanasia
    Position Statement on Euthanasia The Indian Association of Palliative Care opposes euthanasia in all its forms. Good symptom control through palliative care can pre-empt the request for euthanasia. Withholding or withdrawing treatment that is medically futile does not amount to euthanasia. The Indian Association of Palliative Care (IAPC) is an association of professionals devoted to the teaching, promotion and delivery of palliative care in the country. Palliative care includes support during therapy, end-of-life care and bereavement support to families. Specialists in the field of palliative care work closely with terminally-ill and dying patients, and are deeply concerned about euthanasia. The debate on euthanasia or mercy killing has been raging for some time in the country. The case of Aruna Shanbaug, who has been lying in a vegetative state in a hospital following a brutal assault more than 4 decades ago, has highlighted the need for a consensus on the issue. Euthanasia has been discussed at legislative levels and rules are being drafted for the approval of the Parliament. The Supreme Court has called for opinions of individuals and organizations working in this area. Members of the IAPC feel it is important to respond to the court. Palliative care specialists the world over are united in their understanding of what euthanasia is, and what it is not. Euthanasia can never be passive, and the very terminology “passive euthanasia” is tragic and scientifically unsound.i Withholding or withdrawing futile treatments or measures that merely prolong life, is medically and ethically right, and is not “euthanasia”. Freedom from pain is a fundamental human rightii and the physician is bound to use drugs or procedures to alleviate pain and suffering.
    [Show full text]
  • Guideline for Palliative Sedation
    Guideline for Palliative Sedation Royal Dutch Medical Association (KNMG) Committee on National Guideline for Palliative Sedation Royal Dutch Medical Association (KNMG) Utrecht, The Netherlands Januari 2009 KNMG Guideline for Palliative Sedation 2009 1 © Royal Dutch Medical Association (KNMG) Postbus 20051 3502 LB Utrecht Tel. 0031 (0)30 282 3322 Fax 0031 (0)30 282 3326 Email [email protected] For the online knowledge file on palliative sedation, see the website www.medischcontact.tv (Guideline in a downloadable form (also suitable for a PDA), e-learning, Web TV broadcast, articles and links) KNMG Guideline for Palliative Sedation 2009 2 Contents page Summary 5 1 Introduction 12 2 What is palliative sedation? 2.1 Relationship between palliative care and palliative sedation 17 2.2 Definition of palliative sedation 18 2.3 Structure of the guideline 20 2.4 Empirical data on the extent of the practice of palliative sedation 20 3 Indications and preconditions for palliative sedation 3.1 Indications for palliative sedation 22 3.2 Preconditions for continuous sedation 25 3.3 An exceptional situation 26 4 The decision-making process 4.1 Timely and open communication 28 4.2 Reasons for considering palliative sedation 29 4.3 Determining whether indications for palliative sedation are present 29 4.4 Discussion with the patient and/or his representative 31 5 Administration of fluids 35 6 Good medical practice 6.1 Preparations 38 6.2 The initiation of sedation 38 6.3 Proportionality 39 6.4 Drugs and method of administration 39 6.5 Morphine
    [Show full text]
  • Palliative Pharmacological Sedation for Terminally Ill Adults (Review)
    Cochrane Database of Systematic Reviews Palliative pharmacological sedation for terminally ill adults (Review) Beller EM, van Driel ML, McGregor L, Truong S, Mitchell G Beller EM, van Driel ML, McGregor L, Truong S, Mitchell G. Palliative pharmacological sedation for terminally ill adults. Cochrane Database of Systematic Reviews 2015, Issue 1. Art. No.: CD010206. DOI: 10.1002/14651858.CD010206.pub2. www.cochranelibrary.com Palliative pharmacological sedation for terminally ill adults (Review) Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 PLAINLANGUAGESUMMARY . 2 BACKGROUND .................................... 3 OBJECTIVES ..................................... 3 METHODS ...................................... 3 RESULTS....................................... 6 Figure1. ..................................... 7 Figure2. ..................................... 11 Figure3. ..................................... 12 DISCUSSION ..................................... 15 AUTHORS’CONCLUSIONS . 16 ACKNOWLEDGEMENTS . 16 REFERENCES ..................................... 17 CHARACTERISTICSOFSTUDIES . 19 DATAANDANALYSES. 37 APPENDICES ..................................... 37 CONTRIBUTIONSOFAUTHORS . 38 DECLARATIONSOFINTEREST . 39 SOURCESOFSUPPORT . 39 DIFFERENCES BETWEEN PROTOCOL AND REVIEW . .... 39 Palliative pharmacological sedation for terminally ill adults (Review) i Copyright © 2015 The Cochrane Collaboration.
    [Show full text]